From a market-cap perspective:$MRK is trading at an ATH$SGEN is trading ~12% below its ATH
— The Fortune Teller @ Wheel of Fortune (@TheFortuneTell5) June 26, 2022
Paying ~$46B, or $250/share, in #Merck shares would reflect a dilution that is likely to be way smaller than the value #Seagen may create.#Health #Healthcare #Biotech #Biotechnology pic.twitter.com/JytxUPJUzs